Abstract
Hypertriglyceridaemia is associated with insulin resistance, hypertension, obesity and diabetes. The management of hypertriglyceridaemia and atherogenic dyslipidaemias increasingly involves the use of several drugs for different aspects of the metabolic syndrome. This review highlights the agents for treatment of blood pressure, weight and blood pressure that reduce triglycerides as a number of drugs used to treat these co-morbidities also lower triglycerides as additional effects beyond their primary actions. Lipid – lowering drugs particularly fibrates and niacin and to a lesser degree statins and omega-3 fatty acids reduce plasma triglyceride levels. Additional reductions can be gained from the appropriate choice of therapies for co-morbid condition as the optimal combinations may offer benefits in improving cardiovascular risk as well as compliance.
Keywords: Triglyceride, insulin resistance, metabolic syndrome, drug, hypoglycaemic agent, anti-hypertensive therapy, lipidlowering drug
Current Drug Targets
Title: Potential Options to Treat Hypertriglyceridaemia
Volume: 10 Issue: 4
Author(s): Adie Viljoen and Anthony S. Wierzbicki
Affiliation:
Keywords: Triglyceride, insulin resistance, metabolic syndrome, drug, hypoglycaemic agent, anti-hypertensive therapy, lipidlowering drug
Abstract: Hypertriglyceridaemia is associated with insulin resistance, hypertension, obesity and diabetes. The management of hypertriglyceridaemia and atherogenic dyslipidaemias increasingly involves the use of several drugs for different aspects of the metabolic syndrome. This review highlights the agents for treatment of blood pressure, weight and blood pressure that reduce triglycerides as a number of drugs used to treat these co-morbidities also lower triglycerides as additional effects beyond their primary actions. Lipid – lowering drugs particularly fibrates and niacin and to a lesser degree statins and omega-3 fatty acids reduce plasma triglyceride levels. Additional reductions can be gained from the appropriate choice of therapies for co-morbid condition as the optimal combinations may offer benefits in improving cardiovascular risk as well as compliance.
Export Options
About this article
Cite this article as:
Viljoen Adie and Wierzbicki S. Anthony, Potential Options to Treat Hypertriglyceridaemia, Current Drug Targets 2009; 10 (4) . https://dx.doi.org/10.2174/138945009787846380
DOI https://dx.doi.org/10.2174/138945009787846380 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index To Volume 2
Current Cardiology Reviews Weight Loss in Older Persons: New Therapeutic Approaches
Current Pharmaceutical Design Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design The Interaction of Depression and Diabetes: A Review
Current Diabetes Reviews Tocotrienols and Cardiovascular Health
Current Pharmaceutical Design Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Sudden Infant Death Syndrome from Epidemiology to Pathophysiology
Current Pediatric Reviews Adiponectin as a Target in Obesity-related Inflammatory State
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus
Endocrine, Metabolic & Immune Disorders - Drug Targets Season of Birth Effects on Reproduction in Women
Current Women`s Health Reviews Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry Editorial [Hot Topic:Dietary Determinants of the Metabolic Syndrome (Guest Editor: Luc Tappy Co-Editors: Jacques Delarue and Kim-Anne Le)]
Current Nutrition & Food Science Identification of Genes for a Complex Trait: Examples from Hypertension
Current Pharmaceutical Biotechnology Glucose Sensors Based on Core@Shell Magnetic Nanomaterials and Their Application in Diabetes Management: A Review
Current Pharmaceutical Design New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Involvement of Cytokines and Inflammation in Catecholamine-Induced Pulmonary Injury in Rats
Vascular Disease Prevention (Discontinued) Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology